

Medical Oncology: the unmet needs and how we meet them

John Bridgewater and Juan Valle

CCA-UK Inaugural Meeting

07 December 2018




Acknowledgement | 1301 UK patients have participated in NCRI Academic studies*

*ABC-01 to -08; BILCAP; PHOTOSTENT-2

Advanced disease | limited treatment options


ABC-02



- For our current treatment
 - Who are the “rapid non-responders”?
 - Are there sub-groups who benefit most?
- Need for new agents
 - Acelarin
 - Immunotherapy
- Should we intensify?
 - FOLFIRINOX?
 - CisGem + nab-paclitaxel?
 - Chemosaturation?
- Efficacy vs quality of life

Need to accelerate progress

Second-line | no established treatment options




Completed recruitment² | results
ASCO 2019


- **Systematic review¹**
 - n=895 patients
 - No conclusion regarding best approach
 - Patients are willing to participate in clinical trials
- **Need to accelerate progress**

Incorporating radiation therapy

ABC-07





SIRCCA



- Need to determine optimal sequencing
- Need to explore novel approaches

Chemo and surgery | getting more patients to cure


Lessons from CRLM




- Neo-adjuvant
- Borderline resectable

Anatomical heterogeneity | lump or split?

ABC-02




ABC-02 + BT22




ADVANCED DISEASE

BILCAP



EARLY-STAGE DISEASE

Driver mutations | emerging and new



Driver mutations | targeted in practice

MOSCATO study | 1035 patients
 ≥1 prior systemic treatment, PS 0-1
 Available tissue

High-throughput molecular analysis



- **BTC** n=43
- **Evaluable** n=34
- **Druggable alteration** n=23
- **Treated** n=18

ORR 33%

DCR 88%

Median OS 17 mo vs. 5 mo

[HR 0.29; 95% CI, 0.11-0.76; p< 0.008).




Translational unmet needs and how we meet them

- Optimising translational research
- Molecular understanding of CCA (prognostic and therapeutic)
- Accessibility of cancer centre care (research and expertise)
- International collaboration
- Co-ordinated basic science
- Translationally driven clinical studies
- Profile and education (and politics?)
- Harmonisation of regulation and funding

A translational framework

ecmc



LifeArc

CATAPULT
Medicines Discovery


Accelerated
Access
Review of innovative medicines and medical technologies
supported by Wellcome Trust

NHS
National Institute for
Health Research
MICs


TheAHSNNetwork



First gap in
translation



Second gap in translation



Adapted from Wareham et al, 2009

